Roots Analysis
AUGUST 16, 2023
Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract manufacturing service providers to cater to the urgent global demand.
Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 6, 2021
million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5
Roots Analysis
FEBRUARY 21, 2022
These kits require less input sample, produce sufficient DNA / RNA libraries with minimum errors and are compatible with a broad range of input samples, including blood, cells, plasma and saliva. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Nanoparticles Contract Manufacturing.
pharmaphorum
OCTOBER 27, 2020
Things were looking promising for the project as recently as last month, when BioSig said it was doubling the size of the study from 40 to 80 patients and hiring a contract manufacturer to produce supplies for a phase 3 trials programme.
Roots Analysis
FEBRUARY 18, 2022
In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.
pharmaphorum
JANUARY 7, 2021
The biotech would likely struggle to supply without the help of its new big pharma partner, although it has been expanding its production capacity in the last few weeks with the help of contract manufacturers like Wacker and Fareva.
Expert insights. Personalized for you.
52 
Let's personalize your content